PLENARY

HESI Emerging Issues Session
12 June 2013
Rapporteur Reports
(5 mins each)

Group 1: Alternatives to Animal Testing
Craig Rowlands (Dow)

Group 2: Exposure Science
Don Marsh (Merck)

Group 3: Epigenetics in Safety and Risk Assessment
Mark Hurtt (Pfizer)

Group 4: In Vitro to In Vivo Extrapolation
Tim Pastoor (Syngenta)

Group 5: Safety Assessment for New Therapeutic Modalities
Mike Graziano (BMS)

Group 6: Personalized Medicine and Individual Susceptibility
Dave Brewster (Vertex)
Open Discussion

GENERAL FEEDBACK

POSSIBLE DISCUSSION QUESTIONS:

- In which areas can HESI provide leadership that’s currently lacking?
- New directions, approaches, out-of-the-box thinking?
- Is HESI’s Scientific Portfolio too narrow? Too broad? Are there significant gaps?
- Advice for the EIC and Board PSSC (joint meeting tomorrow afternoon)?
Additional Resources (if needed)
Technical Committees
• Animal alternatives in environmental risk assessment
• Application of genomics to mechanism-based risk assessment
• Cardiac safety
• Developmental and reproductive toxicology (DART)
• Genetic toxicology
• Immunotoxicology
• Protein allergenicity
• Risk assessment for the 21st century (Risk 21)

Project Committees
• Biomarkers of nephrotoxicity
• Development of methods for a tiered approach to assess bioaccumulation of chemicals
• Use of imaging for translational safety assessment
• Vaccines and adjuvants safety

Emerging Issues Subcommittees
• Evaluating causality in epidemiologic studies
• Frameworks for alternative chemical assessment and selection of safer, sustainable alternatives
• Translational biomarkers of neurotoxicity

In Program Book, Emerging Issues Session tab
Each axis appearing on the 2010-2020 HESI Combined Challenges Map is a continuum. All issues on the map are of high importance/impact based on prioritization by the participants in the 2009 HESI mapping exercise. "Relative impact" is a qualitative measure of importance among high priority topics. The location of issues along the "time" continuum is an approximation of when the topic is likely to become a major issue in the timeframe from 2010 to 2020.
ILSI Health and Environmental Sciences Institute
Strategic Plan: 2011-2015

1. Create Definitive Scientific Solutions
   - Focus on Program Areas in Translational Biology, Risk Assessment, Environmental Toxicology and New Technology and Approaches
   - Identify and Prioritize New Scientific Issues to Increase Alignment with the Scientific Map
   - Deliver Quality Scientific Results

2. Ensure Recognition of HESI’s Value and Contributions
   - Evaluate and Continuously Improve Recognition of HESI’s Value and Contribution
   - Develop and Implement a Proactive Engagement and Communications Plan for HESI
   - Increase HESI’s Outreach to and Recognition With Key Stakeholders

3. Optimize HESI’s Organizational Effectiveness
   - Align Organizational Structure with Strategic Requirements
   - Attract and Engage Quality Scientists and Optimize Tripartite Composition
   - Ensure Effective Project Management to Deliver Outcomes in a Timely Fashion
   - Ensure Appropriate Staffing and Financial Resources to Support Programs

4. Assure Transparency of Scientific and Communications Processes